IFP Advisors’s GT Biopharma GTBP Stock Holding History

IFP Advisors’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2	Closed	-$16	–	3410
2023 Q2	$16	Hold	2	–	–	﹤0.01%	3424
2023 Q1	$259	Hold	2	–	–	﹤0.01%	3254
2022 Q4	$1K	Buy	+2	New	+$100	﹤0.01%	4357

Other funds holding GTBP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BFS

Baskin Financial Services Toronto, Ontario, Canada $1.27B AUM 9.68% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IFP Advisors's GTBP Position: Q3 2023 in Review

IFP Advisors sold out of GT Biopharma (GTBP) in Q3 2023, closing a stake of 2 shares — an estimated $16 sold.

IFP Advisors first reported a position in GTBP in Q4 2022 and held it in 3 quarters. The position peaked at $1K in Q4 2022. 32 funds tracked by Wall St. Rank hold GTBP as of Q3 2023.

IFP Advisors reported no remaining GT Biopharma position as of Q3 2023 after selling out during the quarter.
IFP Advisors sold 2 GT Biopharma shares in Q3 2023, an estimated $16.
IFP Advisors first reported a position in GT Biopharma in Q4 2022 and held it in 3 quarters.
IFP Advisors's GT Biopharma position peaked at $1K in Q4 2022.
32 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2023.

Based on IFP Advisors's 13F filing for Q3 2023, filed 12 Oct 2023.